Newsroom
Strive to Deliver Breakthroughs
-
January 13, 2022
Harbour BioMed Completes the First Interim Analysis of Phase III Clinical Trial of Tanfanercept
Cambridge, MA, Rotterdam, NL, Suzhou, CN — January 13, 2022 Harbour BioMed (“HBM”, HKEX: 02142) announced that, the Company has ...
View more -
January 04, 2022
Harbour BioMed Announces Dosing of First Patient of Two Phase I Trials for Next-Generation Anti-CTLA-4 Antibody HBM4003
Cambridge, MA, Rotterdam, NL, Suzhou, CN — January 4, 2022 Harbour BioMed (“HBM”, HKEX: 02142) announced that, its next generati...
View more -
October 19, 2021
Harbour BioMed Announces Dosing of First Patient of Batoclimab Phase II Trial in Patients with Thyroid Eye Disease
Cambridge, MA, Rotterdam, NL, Suzhou, CN— October 19, 2021 Harbour BioMed (“HBM”, HKEX: 02142) announced that, the clinical...
View more -
September 27, 2021
Harbour BioMed Announces Dosing of First Patient of Batoclimab Phase III Trial in Patients with Generalized Myasthenia Gravis
Cambridge, MA, Rotterdam, NL, Suzhou, CN— September 27, 2021 Harbour BioMed (“HBM”, HKEX: 02142) announced that, the clinical tr...
View more -
September 14, 2021
Harbour BioMed Announces NMPA Approval of Two IND Applications for Next-Generation Anti-CTLA-4 Antibody HBM4003
Cambridge, MA, Rotterdam, NL, Suzhou, CN - September 14, 2021 Harbour BioMed (“HBM”, HKEX: 02142) announced that the China Nation...
View more -
September 13, 2021
Harbour BioMed Announces Phase I Study Positive Results on Next-Generation Anti-CTLA-4 Antibody HBM4003
Cambridge, MA, Rotterdam, NL, Suzhou, CN - September 13, 2021 Harbour BioMed (“HBM”, HKEX: 02142) announced positive results from...
View more -
September 01, 2021
Harbour BioMed Announces IND Approval for Phase II Trial of Anti-FcRn Batoclimab in Chronic Inflammatory Demyelinating Polyneuropathy in China
Cambridge, MA, Rotterdam, NL, Suzhou, CN - September 1, 2021 Harbour BioMed (“HBM”, HKEX: 02142) today announced that the Center ...
View more -
August 31, 2021
Harbour BioMed Reports 2021 Interim Results: Product Development Breakthroughs Continue to Unlock Value of Integrated Antibody Discovery Platform
CAMBRIDGE, Mass.; Suzhou, China; Rotterdam, Netherlands - August 31, 2021 Harbour BioMed (“HBM”, or the "Company”; HKEX: 02...
View more -
July 26, 2021
HBM Presents Phase I Data on Next-Generation Anti-CTLA-4 Antibody at ESMO Congress 2021
Cambridge, MA, Rotterdam, NL, Shanghai/Suzhou, CN – July 26, 2021 Harbour BioMed (“HBM”, HKEX: 02142) today announced that t...
View more -
July 21, 2021
Mount Sinai Entered into Exclusive License Agreement for Neutralizing SARS-CoV-2 Antibody Derived from Harbour BioMed Technology
Cambridge, MA, Rotterdam, NL, Shanghai/Suzhou, CN – July 21, 2021 Harbour BioMed (“HBM”, HKEX: 02142) today announced that the I...
View more
Copyright © 2025 Harbour BioMed. All Rights Reserved
沪公网安备31011502401396号
沪ICP备19015946号-1